Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd with durvalumab with or without carboplatin in advanced or metastatic non-small cell lung cancer
jRCT2031200449Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of datopotamab deruxtecan, durvalumab and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with dose-limiting toxicities and treatment-emergent adverse events. Started May 2021; status: active, not recruiting.
02
Drugs
datopotamab deruxtecandurvalumabcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031200449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200449.